Abstract
Since 1982, four consecutive studies on childhood acute myeloid leukaemia (AML) (namely LAM-82, -87, -87M and -92) have been conducted in Italy by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) group. The induction therapy of the first three studies consisted of daunorubicin and cytarabine structured in a 3+7 backbone. In the most recent protocol (LAM92), patients received two induction courses including idarubicin, cytarabine and etoposide. Patients with acute promyelocytic leukaemia (20% of diagnoses) were included in LAM-87 and 87M studies. Postremissional therapy significantly changed over time, with an ever-increasing role given to stem cell transplantation (SCT). The long-term outcome of patients enrolled in the LAM-82, 87 and 87M studies was comparable, whereas that of children treated according to LAM-92 study was significantly better (P
| Original language | English |
|---|---|
| Pages (from-to) | 2043-2053 |
| Number of pages | 11 |
| Journal | Leukemia |
| Volume | 19 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2005 |
Fingerprint
Keywords
- Acute promyelocytic luekemia
- Childhood acute myeloid leukaemia
- Stem cell transplantation
ASJC Scopus subject areas
- Hematology
- Cancer Research
Cite this
Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. / Pession, Andrea; Rondelli, R.; Basso, G.; Rizzari, C.; Testi, A. M.; Fagioli, F.; De Stefano, P.; Locatelli, F.
In: Leukemia, Vol. 19, No. 12, 12.2005, p. 2043-2053.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols
AU - Pession, Andrea
AU - Rondelli, R.
AU - Basso, G.
AU - Rizzari, C.
AU - Testi, A. M.
AU - Fagioli, F.
AU - De Stefano, P.
AU - Locatelli, F.
PY - 2005/12
Y1 - 2005/12
N2 - Since 1982, four consecutive studies on childhood acute myeloid leukaemia (AML) (namely LAM-82, -87, -87M and -92) have been conducted in Italy by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) group. The induction therapy of the first three studies consisted of daunorubicin and cytarabine structured in a 3+7 backbone. In the most recent protocol (LAM92), patients received two induction courses including idarubicin, cytarabine and etoposide. Patients with acute promyelocytic leukaemia (20% of diagnoses) were included in LAM-87 and 87M studies. Postremissional therapy significantly changed over time, with an ever-increasing role given to stem cell transplantation (SCT). The long-term outcome of patients enrolled in the LAM-82, 87 and 87M studies was comparable, whereas that of children treated according to LAM-92 study was significantly better (P
AB - Since 1982, four consecutive studies on childhood acute myeloid leukaemia (AML) (namely LAM-82, -87, -87M and -92) have been conducted in Italy by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) group. The induction therapy of the first three studies consisted of daunorubicin and cytarabine structured in a 3+7 backbone. In the most recent protocol (LAM92), patients received two induction courses including idarubicin, cytarabine and etoposide. Patients with acute promyelocytic leukaemia (20% of diagnoses) were included in LAM-87 and 87M studies. Postremissional therapy significantly changed over time, with an ever-increasing role given to stem cell transplantation (SCT). The long-term outcome of patients enrolled in the LAM-82, 87 and 87M studies was comparable, whereas that of children treated according to LAM-92 study was significantly better (P
KW - Acute promyelocytic luekemia
KW - Childhood acute myeloid leukaemia
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=28544433591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28544433591&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2403869
DO - 10.1038/sj.leu.2403869
M3 - Article
VL - 19
SP - 2043
EP - 2053
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 12
ER -